Compass (CMPS) Q2 Loss Improves 27%
Compass Pathways Plc (NASDAQ:CMPS), a clinical-stage mental health company developing psilocybin-based therapies, released its second quarter 2025 results on July 31, 2025. The main headline was a strong clinical update: its lead drug candidate, COMP360 psilocybin, hit its primary goal in a Phase 3 trial for treatment-resistant depression (TRD) with clear statistical and clinical impact. Earnings also slightly exceeded analyst expectations, with a GAAP net loss of $0.41 per share for Q2 2025, better than the consensus estimate of $0.43 per share. There was no revenue, as anticipated for a pre-commercial company. Overall, Q2 2025 demonstrated continued clinical and financial progress—most notably improved operating discipline and a strengthened cash position—though crucial longer-term safety and durability results are still pending.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Compass Pathways specializes in developing psychedelic-based therapies for serious mental health challenges, with its core asset being COMP360, a proprietary psilocybin therapy undergoing advanced clinical trials. The company's main focus is on treatment-resistant depression, a condition where patients do not respond to standard antidepressants, and post-traumatic stress disorder, both of which are large unmet needs in psychiatry.
Source Fool.com
